DAA Therapy and the risk of HCC: Is the Risk Real? What are the Solutions? |
Conferences
eMediNexus Coverage from: 
DAA Therapy and the risk of HCC: Is the Risk Real? What are the Solutions?
Dr Subrat Kumar Acharya, Bhubaneswar,  06 December 2018
Coronavirus Live Count Map India

remove_red_eye 650 Views
COVID-19 Vaccine Updates

Coronavirus Protocols

#Gastroenterology

0 Read Comments                

There is no substantial evidence to associate DAA to apparent enhanced detection frequency of HCCTreatment ambit/reach includes advanced disease which was not possible in interferon era – A population characteristic rather than the therapy.The fibrosis is an important determinant of HCC. Fibrosis reversal is a time consuming event – occurs over long period. Therefore, IFN treated patients included in the studies for comparison were about 5 years post-therapy SVT whereas the DDA treat...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now